CAR-T Therapy

Existing CAR-T trial data are insufficient for infection surveillance because they incompletely report outcomes and often lack pathogen-level detail. Early-phase CAR-T trials commonly provide only six months of safety follow-up. The study includes standard-of-care CD19-directed CAR-T products tisagenlecleucel and axicabtagene.